

# Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023

## Table of Contents

### Cancer Immunotherapy Artificial Intelligence: Executive Summary

The study is designed to give a comprehensive overview of the Cancer Immunotherapy Using Artificial Intelligence market segment. Research represents a selection from the mountains of data available of the most relevant and cogent market materials, with selections made by the most senior analysts. Commentary on every aspect of the market from independent analysts creates an independent perspective in the evaluation of the market. In this manner the study presents a comprehensive overview of what is going on in this market, assisting managers with designing market strategies likely to succeed.

Abstract: Artificial Intelligence Applied to Cancer Immunotherapy Vastly Improves Treatments and Outcomes	1
<b>Summary</b>	<b>11</b>
Cancer Immunotherapy Artificial Intelligence (AI) Market Driving Forces	11
Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces	14
Artificial Intelligence Oncology Treatment Market Shares:	16
Cancer Immunotherapy Artificial Intelligence for Hospitals Market Forecasts:	18
<b>1. Cancer Immunotherapy Artificial Intelligence Market Description and Market Dynamics:</b>	<b>22</b>
1.1 Artificial Intelligence Very Big Breakthrough in Cancer Immunotherapy	22
1.2 Ability of AI Solutions To Discover Schemas in Large Databases	23
<b>2. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces</b>	<b>25</b>

and List of Figures

2.1	Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces	25
2.2	Artificial Intelligence Oncology Treatment Market Shares:	27
2.3	Cancer Immunotherapy Artificial Intelligence for Hospitals Market Forecasts:	30
2.4	Worldwide Checkpoint Inhibitor and Oncology Treatment Market Forecasts	38
2.5	Cancer Statistics	41
2.5.1	Cancer Among The Leading Causes Of Death Worldwide	46
2.6	Hospital Artificial Intelligence (AI) Challenges	49
2.7	Hospital Artificial Intelligence Software Prices:	52
2.8	Hospital Artificial Intelligence Regional Segments:	53
<b>3.</b>	<b>Cancer Immunotherapy Hospital Artificial Intelligence</b>	<b>55</b>
<b>Products:</b>		<b>55</b>
3.1	Memorial Sloan Kettering	55
3.1.1	Memorial Sloan Kettering Parker Institute	57
3.1.2	CAR T Immunotherapy	57
3.1.2	T-Cell Therapies from Merck and Bristol-Myers Squibb	58
3.1.3	Memorial Sloan Kettering Cancer Diagnostic Test, MSK-IMPACT	60
3.1.4	Memorial Sloan Kettering Intensified Tumor Testing	61
3.1.5	Memorial Sloan Kettering Effective Sequencing	61
3.1.6	Memorial Sloan Kettering Actionable the most important cancer	
geneTargets		62
3.2	MD Anderson Immune Therapy	63
3.2.1	MD Anderson Immune Therapy	65
3.2.2	MD Anderson Personalized Therapy TNBC Cancer Trials	66
3.3	Partners Dana Farber Immunotherapy	67

and List of Figures

3.3.1	Advanced Melanoma Has Been The Test Case For The Study Of Immune Checkpoint-Inhibiting Therapy	68
3.4	Partners HealthCare, IBM, and GE Healthcare	70
3.5	IBM Watson	72
3.5.1	IBM Genomic And Immunotherapy Supercomputing for Patient Management	75
3.5.2	Mayo Clinic and IBM Watson	76
3.6	Google’s AI Subsidiary DeepMind is Partnering With Another UK hospital	78
3.7	Prognos	78
<b>4.</b>	<b>Hospital Artificial Intelligence Research and Technology:</b>	<b>79</b>
4.1	IBM AI Research	79
4.1.1	Neural Representation of Sketch Drawings	80
4.1.2	IBM Watson Health And Broad Institute Launch Major Research Initiative To Study Why Cancers Become Drug Resistant	81
4.1.3	IBM and Quest Diagnostics	83
4.2	Research at Google	83
4.3	Google and Nvidia Artificial Intelligence	84
<b>5.</b>	<b>Hospital Artificial Intelligence Companies</b>	<b>86</b>
5.1	Alphabet / Google	86
5.1.1	Google Artificial Intelligence Subsidiary DeepMind Healthcare Initiative	86
5.2	Broad Institute of MIT and Harvard	87
5.3	Foundation Medicine	88
?	>120k	88
?	>30	88
?	>200	88

**Cancer Immunotherapy Artificial Intelligence Table of Contents  
and List of Figures**

5.3.1	Foundation Medicine	89
5.4	General Electric (GE)	90
5.4.1	General Electric Revenue by Segment	91
5.4.2	GE Healthcare and Massachusetts General Artificial Intelligence	91
5.5	Gritstone Oncology	94
5.6	IBM	94
5.6.1	IBM Watson Health	94
5.6.2	IBM Active in BWH, MGH Partnership To Advance Artificial Intelligence In Health Care	95
5.6.3	IBM Watson Artificial Intelligence for Oncology	96
5.6.4	IBM Watson Genomics by Quest Diagnostics	97
5.6.5	IBM Watson Healthcare Revenue	98
5.6.6	IBM Watson Solutions Software Healthcare Revenue	98
5.7	Juno Therapeutics	100
5.7.1	Juno Therapeutics Power Of Individualized Cancer Treatment	100
5.7.2	Juno Therapeutics CAR and TCR Technologies	101
5.8	Myriad Genetics	104
5.9	Nvidia	104
5.9.1	NVIDIA	105
5.9.2	Nvidia Revenue	106
5.7.3	Nvidia Customer HeartFlow Medical Technology	107
5.10	Pfizer	107
5.11	Prognos	108
5.11.1	Coding Healthcare Datasets Full Of Unstructured Text	110
5.12	Quest Diagnostics	114

**Cancer Immunotherapy Artificial Intelligence Table of Contents  
and List of Figures**

5.12.1 IBM Personalized Healthcare: Watson Genomics from Quest	
Diagnostics	115
5.12.2 Quest Diagnostics Revenue	116
5.13 Safeguard Scientifics Announces Second Quarter 2017 Financial Results	116
5.13.1 Safeguard Scientifics Prognos DxCloud	117
<b>WinterGreen Research,</b>	<b>118</b>
WinterGreen Research Methodology	119
WinterGreen Research Process	120
Market Research Study	121
WinterGreen Research Global Market Intelligence Company	122
Report Description: Hospital Artificial Intelligence Models Matter	123
Abstract: Artificial Intelligence Applied to Cancer Immunotherapy Vastly Improves Treatments and Outcomes	1
Figure 1. T Lymphocyte	12
Figure 2. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces	14
Figure 3. Healthcare Safety Features Implemented by Artificial Intelligence (AI)	15
Figure 4. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, 2016	17
Figure 5. Cancer Immunotherapy Hospital Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023	20
Figure 6. Cancer Artificial Intelligence Components	23
Figure 7. Hospital Artificial Intelligence Predictive Functions	24

**and List of Figures**

Figure 8. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces	25
Figure 9. Healthcare Safety Features Implemented by Artificial Intelligence (AI)	26
Figure 10. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, 2016	28
Figure 11. Cancer Immunotherapy Artificial Intelligence Systems, Market Shares, Dollars, Worldwide, 2016	29
Figure 12. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023	32
Figure 13. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023	33
Figure 14. AI Replacements for Supervised Manual Techniques For Diagnosis And Care Delivery.	34
Figure 15. Hospital Artificial Intelligence Long-Term Goal	35
Figure 16. Hospital Artificial Intelligence Action Functions	37
Figure 17. Immuno-Oncology Market Applications	39
Figure 18. Key players in the immuno-oncology market	40
Figure 19. Estimated New Cancer Cases in the US in 2017	41
Figure 20. Trends in Cancer Incidence Rates, US, 1975 to 2013	42
Figure 21. Estimated Cancer Deaths in the US in 2017	43
Figure 22. Pancreatic Cancer Survival Rate	45
Figure 23. Trends in Cancer Death Rates Among Males, US 1930 to 2014	46
Figure 24. Hospital Artificial Intelligence (AI) Challenges	49
Figure 25. Hospital Artificial Intelligence (AI) Human Factors	50
Figure 26. IBM 8408 E8E PSeries AIX Power8 Server EPV4 24-Core	52
Figure 27. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, 2016	53
Figure 28. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, 2016	54

**Cancer Immunotherapy Artificial Intelligence Table of Contents  
and List of Figures**

Figure 29. T Lymphocyte	55
Figure 30. MD Anderson Genetic Sequencing Services:	64
Figure 31. MD Anderson Sample quality check (DNA and RNA)	64
Figure 32. MD Anderson Cancer Immunotherapy Custom Services:	65
Figure 33. Partners Dana Farber Immunotherapy Directions	67
Figure 34. Stephen F. Hodi, MD, Director, Partners Dana Farber Melanoma Center; Director, Center for Immuno-Oncology	68
Figure 35. Truven Health Analytics Products	74
Figure 36. IBM TrueNorth Neurosynaptic System	79
Figure 37. AI Makes Words Manageable	80
Figure 38. Foundation Medicine Metrics	88
Figure 39. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Workflow	92
Figure 40. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Center of Excellence	93
Figure 41. Juno Therapeutics Immunotherapy	100
Figure 42. Chimeric Antigen Receptor (CAR) T cell Technology	101
Figure 43. T Cell Receptor (TCR) Technology	102
Figure 44. Tumor Cells' Ability To Develop Resistance	103
Figure 45. NVIDIA Tesla V100 Accelerator	105
Figure 46. Nvidia Interconnect and Memory Parameters	106
Figure 47. Prognos Investors	108
Figure 48. Percent Patients with Abnormally High Test 5 years Prior to First Pancreatic Cancer Diagnosis Stratified by Test and by Year	112
Figure 49. Prognos Pancreatic Cancer Diagnosis Test Result Variance	113
Figure 50. Watson Genomics from Quest Diagnostics Features:	115